Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H6O2S |
Molecular Weight | 154.186 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(S)C=CC=C1
InChI
InChIKey=NBOMNTLFRHMDEZ-UHFFFAOYSA-N
InChI=1S/C7H6O2S/c8-7(9)5-3-1-2-4-6(5)10/h1-4,10H,(H,8,9)
Molecular Formula | C7H6O2S |
Molecular Weight | 154.186 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Thiosalicylic acid is an analgesic and anti-inflammatory agent. It is used (in form of sodium salt) to relieve symptoms of acute gout, painful musculoskeletal conditions, osteoarthritis and rheumatic fever. The drug exerts its action by inhibiting prostaglandin synthesis. Thiosalicylic acid usage is associated with the risk of contact dermatitis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
Palliative | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
|||
Primary | REXOLATE Approved UseTo relieve symptoms of acute gout, to relieve pain from musculoskeletal conditions, to relieve symptoms of osteoarthritis, to treat rheumatic fever. |
PubMed
Title | Date | PubMed |
---|---|---|
Thimerosal in the detection of clinically relevant allergic contact reactions. | 2001 Jul |
|
Simultaneous determination of reduced and oxidized glutathione in peripheral blood mononuclear cells by liquid chromatography-electrospray mass spectrometry. | 2001 Jun 5 |
|
Superoxide dismutase activity and electrochemical study of the binuclear [Cu(TSA)2py]2 complex. | 2002 |
|
Preconcentration of lead with Amberlite XAD-2 and Amberlite XAD-7 based chelating resins for its determination by flame atomic absorption spectrometry. | 2002 Mar 11 |
|
Antimycobacterial and antifungal isosters of salicylamides. | 2003 Aug |
|
The thiol reagent, thimerosal, irreversibly inhibits meiosis reinitiation in mouse oocyte when applied during a very early and narrow temporal window: a pharmacological analysis. | 2003 Aug |
|
Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study. | 2003 Dec |
|
A new LC/MS-method for the quantitation of acrylamide based on a stable isotope dilution assay and derivatization with 2-mercaptobenzoic acid. Comparison with two GC/MS methods. | 2003 Dec 31 |
|
An alternative synthesis of 2-(N-arylhydrazono)-1-benzothiophen-3-ones. | 2003 Mar 7 |
|
Zn(II)-catalyzed thiolysis of oxiranes in water under neutral conditions. | 2003 Oct 17 |
|
Effect of taxol and okadaic acid on microtubule dynamics in thimerosal-arrested primary mouse oocytes: a confocal study. | 2003 Sep |
|
Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres. | 2004 Apr 1 |
|
Development of a direct-binding chloramphenicol sensor based on thiol or sulfide mediated self-assembled antibody monolayers. | 2004 Feb 15 |
|
Using model complexes to augment and advance metalloproteinase inhibitor design. | 2004 May 17 |
|
Self-assembly of dialkyltin moieties and mercaptobenzoic acid into macrocyclic complexes with hydrophobic "pseudo-cage" or double-cavity structures: supramolecular infrastructures involving intermolecular C-H...S weak hydrogen bonds and pi-pi interactions. | 2005 Dec 23 |
|
Determination of mercury complexation in coastal and estuarine waters using competitive ligand exchange method. | 2005 Sep 1 |
|
Uncoupling of ATP-mediated calcium signaling and dysregulated interleukin-6 secretion in dendritic cells by nanomolar thimerosal. | 2006 Jul |
|
Effect of subinhibitory concentration of some established and experimental antifungal compounds on the germ tube formation in Candida albicans. | 2007 |
|
Competing ligand exchange-solid phase extraction method for the determination of the complexation of dissolved inorganic mercury (II) in natural waters. | 2007 Aug 29 |
|
Heterocycles [h]fused onto 4-oxoquinoline-3-carboxylic acid, part IV. Convenient synthesis of substituted hexahydro [1,4]thiazepino[2,3-h]quinoline-9-carboxylic acid and its tetrahydroquino[7,8-b]benzothiazepine homolog. | 2007 Jul 27 |
|
Relationship between redox activity and chemical speciation of size-fractionated particulate matter. | 2007 Jun 7 |
|
Determination of acrylamide during roasting of coffee. | 2008 Aug 13 |
|
Development of a stable isotope dilution assay for the quantitation of glycidamide and its application to foods and model systems. | 2008 Aug 13 |
|
Cleavage of focal adhesion kinase is an early marker and modulator of oxidative stress-induced apoptosis. | 2008 Jan 10 |
|
Thimerosal and the relevance of patch-test reactions in children. | 2008 Sep-Oct |
|
[1,2-Bis(diphenyl-phosphino)ethane-κP,P'](2-carboxyl-atothio-phenolato-κO,S)nickel(II) methanol solvate. | 2009 Jan 8 |
|
Mercury exposure, nutritional deficiencies and metabolic disruptions may affect learning in children. | 2009 Oct 27 |
|
Field-assisted synthesis of SERS-active silver nanoparticles using conducting polymers. | 2010 Aug |
|
Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives. | 2010 Jul |
|
Sensitization effect of thimerosal is mediated in vitro via reactive oxygen species and calcium signaling. | 2010 Jul-Aug |
|
Poly[(dimethyl-formamide)(μ(4)-2,2'-sulfanediyldibenzoato)nickel(II)]. | 2010 Mar 6 |
|
2-[(2-Carboxy-phen-yl)disulfan-yl]benzoic acid-4,4'-bipyridyl N,N'-dioxide (1/2). | 2010 May 26 |
|
14-(1,3-Benzodioxol-5-yl)-7,14-dihydro-dibenzo[a,j]acridine. | 2010 Nov 6 |
Sample Use Guides
Acute gout: initial dose is 100 mg every 3 to 4 hours for 2 days, then 100 mg daily. Painful musculoskeletal conditions: 50 to 100 mg daily or every other day. Osteoarthritis: 10 mg 3 times/week for several weeks then once a week, usually up to a total dosage of 2.5 g. Rheumatic fever: initial dose is 100 to 150 mg every 4 to 8 hours for 3 days, then 100 mg two times daily.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8298817
Human platelets were incubated with thiosalicylic acid at 0.5 mM for 3 min in the presence of 1,2
and 1,3-glyceryl dinitrate. A concentration-dependent inhibition of platelet aggregation was observed.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:17:19 GMT 2023
by
admin
on
Fri Dec 15 15:17:19 GMT 2023
|
Record UNII |
CIP6LXN5XW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
78903
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
660640
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
THIOSALICYLIC ACID
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
C441201
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
2184
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
5443
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
322165
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
DTXSID4049032
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
59124
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
91099
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
ALTERNATIVE | |||
|
CIP6LXN5XW
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
59127
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
m10783
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
147-93-3
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
2739
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
DB14026
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY | |||
|
C87327
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
100000183747
Created by
admin on Fri Dec 15 15:17:20 GMT 2023 , Edited by admin on Fri Dec 15 15:17:20 GMT 2023
|
PRIMARY | |||
|
205-704-3
Created by
admin on Fri Dec 15 15:17:19 GMT 2023 , Edited by admin on Fri Dec 15 15:17:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |